Adaptive Biotechnologies Stock
DNA sequencing for cancer therapy & research
Sign up today and learn more about Adaptive Biotechnologies Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Adaptive Biotechnologies Stock
Adaptive Biotechnologies aims to help scientists look at the immune system in a new way, with a combination of DNA sequencing and high-powered computation, to analyze the DNA sequences that make up the immune system. Unlike other cell types, which operate on a fixed set of code from the human genome, immune system cells rearrange their DNA constantly in response to shifting threats in the environment. Sometimes the immune system malfunctions and begins attacking healthy tissues (i.e., autoimmune diseases) or certain immune system cells start proliferating out of control (i.e., cancer).
By digging into the immune cell sequences, Adaptive is aiming to create a map of human immune system responses to threats. Armed with this information, Adaptive seeks to develop blood tests that alert doctors when people are fighting specific diseases. Eventually, Adaptive wants to create a universal blood test that detects any disease a body might be fighting. Although such an all-encompassing test may be 10 years away, intermediate tests will come much sooner, according to CEO Chad Robins.
Adaptive was founded in 2009 by Chad Robins, Christopher Carlson, and Harlan Robins and is based in Seattle, Washington. The company has raised capital from investors such as Microsoft, Matrix Capital Management, Tiger Management and Viking Global Investors.
Overview of Adaptive Biotechnologies:
Source: WBBA TV
Co-Founder and CEO
Co-Founder and Head of Innovation